La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Eléments de l'association

R. Grondin15
Récepteur dopaminergique D127
R. Grondin Sauf Récepteur dopaminergique D1" 5
Récepteur dopaminergique D1 Sauf R. Grondin" 17
R. Grondin Et Récepteur dopaminergique D1 10
R. Grondin Ou Récepteur dopaminergique D1 32
Corpus1799
\n\n\n\n \n

List of bibliographic references

Number of relevant bibliographic references: 10.
Ident.Authors (with country if any)Title
000B60 M. Goulet [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; S. Maltais [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada]Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-Monkeys
000C60 V. D. Doan [Canada] ; R. Grondin [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada]Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys
000C62 R. Grondin [Canada] ; M. Goulet [Canada] ; M. Morissette [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada]Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958
000C65 R. Grondin [Canada] ; V. D. Doan ; L. Gregoire ; P. J. BedardD1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys
000C69 F. Calon [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; R. Grondin [Canada] ; P. J. Blanchet [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada]Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys : effects on basal ganglia GABAA/ benzodiazepine receptor complex and GABA content
000D62 R. Grondin [Canada] ; P. J. Bedard [Canada] ; D. R. Britton [États-Unis] ; K. Shiosaki [États-Unis]Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929 : An acute study in parkinsonian levodopa-primed monkeys
000E28 M. Goulet [Canada] ; R. Grondin ; P. J. Blanchet ; P. J. Bedard ; T. Di Paolo [Canada]Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode to not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys
000E29 P. J. Blanchet [Canada] ; R. Grondin ; P. J. BedardDyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates
000E31 P. J. Blanchet [Canada] ; R. Grondin [Canada] ; P. J. Bedard [Canada] ; K. Shiosaki [États-Unis] ; D. R. Britton [États-Unis]Dopamine D1 receptor desensitization profile in MPTP-lesioned primates
000E69 P. J. Bedard [Canada] ; B. Gomez-Mancilla [Canada] ; P. Blanchet [Canada] ; R. Grondin [Canada] ; T. Dipaolo [Canada] ; SETHY ; PIERCEY ; CHASE ; WISE ; PERLMUTTER ; RANHOSKYDopamine-receptor families and the treatment of Parkinson's disease. Discussion

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022